Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cutaneous Melanoma, Stage III: early-phase trial registry
2 of 3 indexed Cutaneous Melanoma, Stage III trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Cutaneous Melanoma, Stage III: 3 US clinical trials tracked, 2 recruiting.
Cutaneous Melanoma, Stage III is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Melanoma Institute Australia, running 1 of these trials.
Enrollment posture brief
Registry condition cutaneous-melanoma-stage-iii
OPEN 2 | RECR 67% | LATE 0 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Cutaneous Melanoma, Stage III lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cutaneous Melanoma, Stage III on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cutaneous Melanoma, Stage III is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
The Multicentre Selective Lymphadenectomy Trial - 3
Melanoma Institute Australia
NCT07049276
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
University of California, San Francisco
NCT07148245
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Emory University
NCT03719131
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cutaneous Melanoma, Stage III records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cutaneous Melanoma, Stage III trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cutaneous Melanoma, Stage III page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Cutaneous Melanoma, Stage III trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma Institute Australia sponsors the most Cutaneous Melanoma, Stage III trials on record, review their full trial history before evaluating a specific study. See Melanoma Institute Australia's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cutaneous Melanoma, Stage III condition card totals 3 registered trials; most-linked intervention Rituximab and Hyaluronidase Human; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.